GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » Gross Margin %

HSCS (HeartSciences) Gross Margin % : 0.00% (As of Jan. 2025)


View and export this data going back to 2022. Start your Free Trial

What is HeartSciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. HeartSciences's Gross Profit for the three months ended in Jan. 2025 was $0.00 Mil. HeartSciences's Revenue for the three months ended in Jan. 2025 was $0.00 Mil. Therefore, HeartSciences's Gross Margin % for the quarter that ended in Jan. 2025 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for HeartSciences's Gross Margin % or its related term are showing as below:


During the past 5 years, the highest Gross Margin % of HeartSciences was 68.42%. The lowest was 28.13%. And the median was 42.86%.

HSCS's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 52.5
* Ranked among companies with meaningful Gross Margin % only.

HeartSciences had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for HeartSciences was 0.00% per year.


HeartSciences Gross Margin % Historical Data

The historical data trend for HeartSciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences Gross Margin % Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24
Gross Margin %
28.13 57.69 42.86 40.00 68.42

HeartSciences Quarterly Data
Apr20 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.67 - - - -

Competitive Comparison of HeartSciences's Gross Margin %

For the Medical Devices subindustry, HeartSciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartSciences's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where HeartSciences's Gross Margin % falls into.


;
;

HeartSciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

HeartSciences's Gross Margin for the fiscal year that ended in Apr. 2024 is calculated as

Gross Margin % (A: Apr. 2024 )=Gross Profit (A: Apr. 2024 ) / Revenue (A: Apr. 2024 )
=0 / 0.019
=(Revenue - Cost of Goods Sold) / Revenue
=(0.019 - 0.006) / 0.019
=68.42 %

HeartSciences's Gross Margin for the quarter that ended in Jan. 2025 is calculated as


Gross Margin % (Q: Jan. 2025 )=Gross Profit (Q: Jan. 2025 ) / Revenue (Q: Jan. 2025 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HeartSciences  (NAS:HSCS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HeartSciences had a gross margin of N/A% for the quarter that ended in Jan. 2025 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


HeartSciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of HeartSciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartSciences Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092